In this article we are going to delve into the topic of Pentomone and explore its many facets. Pentomone is a topic that has aroused great interest in various areas, from science to popular culture. Throughout history, Pentomone has been the subject of debate, research and reflection, and remains relevant today. We will delve into the different perspectives that exist on Pentomone, addressing its importance, its implications and its impact on society. Through this article, we aim to offer a comprehensive and updated vision of Pentomone, with the aim of enriching knowledge and promoting reflection on this fascinating topic.
![]() | |
Clinical data | |
---|---|
Other names | Lilly 113935; LY-113935 |
Drug class | Nonsteroidal antiandrogen |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C24H26O5 |
Molar mass | 394.467 g·mol−1 |
3D model (JSmol) | |
| |
|
Pentomone (INN , USAN ) (developmental code name Lilly 113935 or LY-113935) is a nonsteroidal antiandrogen (NSAA) described as a "prostate growth inhibitor" which was never marketed. It was synthesized and assayed in 1978.
Condensation of two equivalents of o-vanillin with 4,4-dimethylcyclohexadienone (2) gives the five-ring ketone derivative (3). The reaction may be visualized as initial conjugate addition of phenoxide to the enone followed by interception of the resulting anion by the aldehyde carbonyl group. Catalytic hydrogenation then reduces both olefin pi-bonds as well as the ketone, to give (4). Re-oxidation of the alcohol thus formed with pyridinium chlorochromate affords pentomone.